Nanobiotix S.A. ADR (NBTX) News

Nanobiotix S.A. ADR (NBTX): $3.65

-0.15 (-3.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NBTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 487

in industry

Filter NBTX News Items

NBTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NBTX News Highlights

  • NBTX's 30 day story count now stands at 4.
  • Over the past 1 day, the trend for NBTX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about NBTX are MD and VIEW.

Latest NBTX News From Around the Web

Below are the latest news stories about Nanobiotix SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

PARIS, February 10, 2022--Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Yahoo | February 10, 2022

Why Phibro Shares Are Trading Higher Today?

View more earnings on DYAISee more from BenzingaEnsign Group Shares Gain On Mixed Q4 Results, Better-Than-Expected FY22 OutlookNanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Yahoo | February 10, 2022

Nanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient

Nanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology. The case study reports on the first patient treatment experience with potential first-in-class radioenhancer NBTXR3 in pancreatic ductal adenocarcinoma. Nanobiotix and MD Anderson are collaborating to expand the development of NBTXR3 beyond the Company's priority pathways in locally advanced head and neck squamous cell carcinoma and immunotherapy. This ongoing P

Yahoo | February 10, 2022

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

PARIS & CAMBRIDGE, Mass., February 09, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of a peer-reviewed case study by researchers at The University of Texas MD Anderson Cancer Center in Clinical and Translational Radiation Oncology. The case study reports on the first patient experience o

Yahoo | February 9, 2022

NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

PARIS & CAMBRIDGE, Mass., January 26, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 in the Journal of Nanobiotechnology.

Yahoo | January 26, 2022

NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets

PARIS & CAMBRIDGE, Mass., January 10, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided a corporate update highlighting key priorities and anticipated development milestones for 2022.

Yahoo | January 10, 2022

Eargo, Nanobiotix top healthcare gainers, Aligos, Berkeley Lights among losers

No summary available.

Seeking Alpha | January 6, 2022

Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment

By Sam Boughedda

Yahoo | January 6, 2022

Nanobiotix enrolls 1st patient in phase 3 trial of NBTXR3 in head, neck cancer

No summary available.

Seeking Alpha | January 5, 2022

NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

PARIS & CAMBRIDGE, Mass., January 05, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX – the "Company"), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the first patient has been enrolled in NANORAY-312, a global, open-label, two-arm, randomized, Investigator’s Choice phase III registration study that is designed to investigate the efficacy and safety of radiotherapy-

Yahoo | January 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.1406 seconds.